145096-57-7

Basic information

• Product Name: 6-Fluoro-benzooxazole-2-thiol
• Synonyms: 6-Fluoro-benzooxazole-2-thiol;6-Fluoro-1,3-benzoxazole-2-thiol
• CAS NO: 145096-57-7
• Molecular Formula: C₇H₄FNOS
• Molecular Weight: 169.18
• Mol File: 145096-57-7.mol
• Article Data: 13

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 6-Fluoro-benzooxazole-2-thiol(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Fluoro-benzooxazole-2-thiol(145096-57-7)
• EPA Substance Registry System: 6-Fluoro-benzooxazole-2-thiol(145096-57-7)

Safety Data

• Hazardous Substances Data: 145096-57-7(Hazardous Substances Data)

Upstream product

• 140-89-6 potassium ethyl xanthogenate 
• 53981-24-1 2-amino-5-fluorophenol 
• 446-36-6 5-fluoro-2-nitrophenol 
• 75-15-0 carbon disulfide 

Downstream Products

• 153403-53-3 2-chloro-6-fluoro-1,3-benzoxazole 
• 1374820-09-3 C₁₇H₁₆Cl₂FN₃O 
• 1378110-16-7 N-(2-(4-(6-fluorobenzo[d]oxazol-2-yl)piperazine-1-carbonyl)phenyl)-5-(trifluoromethyl)pyridine-2-sulfonamide 
• 1378110-75-8 C₁₈H₁₇FN₄O₂ 
• 1246609-07-3 6-fluoro-2-piperazin-1-yl-benzooxazole 

Relevant articles and documents

HMOX1 inducers

The present invention is related to compounds of structure (I) as heme oxygenase 1 (HMOX 1) inducers. The present invention is also related a method of controlling the activity or the amount, or both the activity and the amount, of heme-oxygenase 1 in a mammalian subject. The definitions of the variables are provided herein.

ANTIBIOTIC COMPOUNDS

The present invention relates to antibiotic compounds of formula (I), to compositions containing these compounds and to methods of treating bacterial diseases and infections using the compounds. The compounds find application in the treatment of infection with, and diseases caused by, Gram-positive and/or Gram-negative bacteria, and in particular in the treatment of infection with, and diseases caused by, Neisseria gonorrhoeae.

2-Aminobenzoxazole ligands of the hepatitis C virus internal ribosome entry site

2-Aminobenzoxazoles have been synthesized as ligands for the hepatitis C virus (HCV) internal ribosome entry site (IRES) RNA. The compounds were designed to explore the less basic benzoxazole system as a replacement for the core scaffold in previously discovered benzimidazole viral translation inhibitors. Structure-activity relationships in the target binding of substituted benzoxazole ligands were investigated.